MX2023013412A - Métodos y composiciones para monitorear el tratamiento de mieloma múltiple recidivante y/o refractario. - Google Patents

Métodos y composiciones para monitorear el tratamiento de mieloma múltiple recidivante y/o refractario.

Info

Publication number
MX2023013412A
MX2023013412A MX2023013412A MX2023013412A MX2023013412A MX 2023013412 A MX2023013412 A MX 2023013412A MX 2023013412 A MX2023013412 A MX 2023013412A MX 2023013412 A MX2023013412 A MX 2023013412A MX 2023013412 A MX2023013412 A MX 2023013412A
Authority
MX
Mexico
Prior art keywords
multiple myeloma
methods
treatment
relapsing
monitor
Prior art date
Application number
MX2023013412A
Other languages
English (en)
Spanish (es)
Inventor
Kodandaram Pillarisetti
Jenna Goldberg
Suzette Girgis
Lin Shun Xin Wang
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023013412A publication Critical patent/MX2023013412A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013412A 2021-05-11 2022-05-11 Métodos y composiciones para monitorear el tratamiento de mieloma múltiple recidivante y/o refractario. MX2023013412A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163187344P 2021-05-11 2021-05-11
PCT/US2022/072247 WO2022241430A1 (en) 2021-05-11 2022-05-11 Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma

Publications (1)

Publication Number Publication Date
MX2023013412A true MX2023013412A (es) 2024-02-27

Family

ID=82399377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013412A MX2023013412A (es) 2021-05-11 2022-05-11 Métodos y composiciones para monitorear el tratamiento de mieloma múltiple recidivante y/o refractario.

Country Status (10)

Country Link
US (2) US20220373550A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337962A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520898A (cg-RX-API-DMAC7.html)
KR (1) KR20240005919A (cg-RX-API-DMAC7.html)
CN (1) CN117295949A (cg-RX-API-DMAC7.html)
AU (1) AU2022273326A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219969A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013412A (cg-RX-API-DMAC7.html)
TW (1) TW202309522A (cg-RX-API-DMAC7.html)
WO (1) WO2022241430A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
EP4698217A1 (en) * 2023-04-19 2026-02-25 Janssen Biotech, Inc. Methods for treating multiple myeloma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
US20130101599A1 (en) * 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
AU2015357535B2 (en) * 2014-12-05 2020-05-14 Eureka Therapeutics, Inc. Antibodies targeting G-protein coupled receptor and methods of use
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
WO2017210617A2 (en) * 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN112955748A (zh) * 2018-10-31 2021-06-11 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
BR112022008522A2 (pt) * 2019-11-05 2022-07-26 Celgene Corp Usos de receptores de antígeno quimérico anti-bcma

Also Published As

Publication number Publication date
CA3219969A1 (en) 2022-11-17
EP4337962A1 (en) 2024-03-20
WO2022241430A1 (en) 2022-11-17
TW202309522A (zh) 2023-03-01
KR20240005919A (ko) 2024-01-12
JP2024520898A (ja) 2024-05-27
AU2022273326A1 (en) 2024-01-04
US20250362298A1 (en) 2025-11-27
US20220373550A1 (en) 2022-11-24
CN117295949A (zh) 2023-12-26

Similar Documents

Publication Publication Date Title
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
PH12021552497A1 (en) Enzyme inhibitors
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
JOP20230037A1 (ar) مثبطات sarm1
MX378283B (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreina plasmatica.
MD3240554T2 (ro) Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
EP3976595A4 (en) SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF
MX382562B (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
EA201991455A1 (ru) Композиции и способы лечения дефицита альфа-1-антитрипсина
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
ZA201904522B (en) Heterocyclic inhibitors of mct4
GEAP202316332A (en) Cdk2 inhibitors and methods of using the same
EP3618807A4 (en) HEARING LOSS PREVENTION COMPOSITIONS AND METHODS
MA55087A (fr) Compositions et procédés de traitement de laminopathies
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2022000811A (es) Inhibidores de enzimas.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX382996B (es) Inhibidores de pcna
EP3833340A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
EA202090565A1 (ru) Композиции и способы лечения диффузной в-крупноклеточной лимфомы